TrialHaematologica2009

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.

Thomas Ernst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.